431 related articles for article (PubMed ID: 32956453)
21. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.
Dima D; Davis JA; Ahmed N; Jia X; Sannareddy A; Shaikh H; Shune L; Kaur G; Khouri J; Afrough A; Strouse C; Lochner J; Mahmoudjafari Z; Raza S; Valent J; Anderson LD; Anwer F; Abdallah AO; Hashmi H
Transplant Cell Ther; 2024 Mar; 30(3):308.e1-308.e13. PubMed ID: 38151105
[TBL] [Abstract][Full Text] [Related]
22. CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.
Firestone RS; McAvoy D; Shekarkhand T; Serrano E; Hamadeh I; Wang A; Zhu M; Qin WG; Patel D; Tan CR; Hultcrantz M; Mailankody S; Hassoun H; Shah US; Korde N; Maclachlan KH; Landau HJ; Scordo M; Shah GL; Lahoud OB; Giralt S; Murata K; Hosszu KK; Chung DJ; Lesokhin AM; Usmani SZ
Blood Adv; 2024 Apr; 8(7):1600-1611. PubMed ID: 37878808
[TBL] [Abstract][Full Text] [Related]
23. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Nooka AK; Rodriguez C; Mateos MV; Manier S; Chastain K; Banerjee A; Kobos R; Qi K; Verona R; Doyle M; Martin TG; van de Donk NWCJ
Cancer; 2024 Mar; 130(6):886-900. PubMed ID: 37960969
[TBL] [Abstract][Full Text] [Related]
24. Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma.
Hua G; Scanlan R; Straining R; Carlson DS
J Adv Pract Oncol; 2023 Mar; 14(2):163-171. PubMed ID: 37009408
[TBL] [Abstract][Full Text] [Related]
25. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.
Frerichs KA; Verkleij CPM; Mateos MV; Martin TG; Rodriguez C; Nooka A; Banerjee A; Chastain K; Perales-Puchalt A; Stephenson T; Uhlar C; Kobos R; van der Holt B; Kruyswijk S; Kuipers MT; Groen K; Vishwamitra D; Skerget S; Cortes-Selva D; Doyle M; Zaaijer HL; Zweegman S; Verona RI; van de Donk NWCJ
Blood Adv; 2024 Jan; 8(1):194-206. PubMed ID: 38052042
[TBL] [Abstract][Full Text] [Related]
26. Teclistamab: First Approval.
Kang C
Drugs; 2022 Nov; 82(16):1613-1619. PubMed ID: 36352205
[TBL] [Abstract][Full Text] [Related]
27. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
Landgren O; Nadeem O
Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
[TBL] [Abstract][Full Text] [Related]
28. Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma.
Moore DC; Granger K; Hill H; Karabinos A; Davis JA
Expert Rev Hematol; 2024 Jun; 17(6):197-200. PubMed ID: 38717927
[No Abstract] [Full Text] [Related]
29. Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody.
Pan D; Richter J
Cancer Manag Res; 2023; 15():741-751. PubMed ID: 37497430
[TBL] [Abstract][Full Text] [Related]
30. BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma.
Wang Y; Li H; Xu W; Pan M; Qiao C; Cai J; Xu J; Wang M; Zhang J
J Immunother; 2020; 43(6):175-188. PubMed ID: 32349046
[TBL] [Abstract][Full Text] [Related]
31. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
Martin TG; Mateos MV; Nooka A; Banerjee A; Kobos R; Pei L; Qi M; Verona R; Doyle M; Smit J; Sun W; Trancucci D; Uhlar C; van de Donk NWCJ; Rodriguez C
Cancer; 2023 Jul; 129(13):2035-2046. PubMed ID: 36991547
[TBL] [Abstract][Full Text] [Related]
32. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
[TBL] [Abstract][Full Text] [Related]
33. BCMAxCD3 Bispecific Yields Robust Responses in Myeloma.
Cancer Discov; 2023 Jun; 13(6):1280. PubMed ID: 37075091
[TBL] [Abstract][Full Text] [Related]
34. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
35. Teclistamab-cqyv in multiple myeloma.
Martino EA; Bruzzese A; Labanca C; Mendicino F; Lucia E; Olivito V; Neri A; Morabito F; Vigna E; Gentile M
Eur J Haematol; 2024 Mar; 112(3):320-327. PubMed ID: 37848191
[TBL] [Abstract][Full Text] [Related]
36. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
Zhao J; Ren Q; Liu X; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
[TBL] [Abstract][Full Text] [Related]
37. Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth.
Wu L; Huang Y; Sienkiewicz J; Sun J; Guiang L; Li F; Yang L; Golubovskaya V
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626122
[TBL] [Abstract][Full Text] [Related]
38. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
39. BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms.
Lee H; Neri P; Bahlis NJ
Blood; 2024 Mar; 143(13):1211-1217. PubMed ID: 38194680
[TBL] [Abstract][Full Text] [Related]
40. Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies.
Keller AL; Reiman LT; Perez de Acha O; Parzych SE; Forsberg PA; Kim PS; Bisht K; Wang H; van de Velde H; Sherbenou DW
Cancer Res Commun; 2024 Mar; 4(3):757-764. PubMed ID: 38421887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
